ライフサイエンスコーパス: trough level

1 t, and were evaluated in relation to the MMF trough level.

2 achieved sustained Abeta reduction of 80% at trough level.

3 the dose was adjusted to maintain the target trough level.

4 ogenic, non-responder patients with adequate trough level.

5 paradigm promoter P(purF) was locked at its trough level.

6 Vancomycin dose was adjusted on the basis of trough levels.

7 ration of SEP-225289, to assess occupancy at trough levels.

8 ions equivalent to maximal achievable plasma trough levels.

9 se of the day, whereas ccg-2 mRNA remains at trough levels.

10 assessed by self-report or SD of tacrolimus trough levels.

11 n a significant decrease in the cyclosporine trough levels.

12 mg/kg b.i.d.; doses were titrated to target trough levels.

13 s adjusted to achieve comparable whole-blood trough levels.

14 tacept with lowered tacrolimus and sirolimus trough levels.

15 us were necessary for maintaining sufficient trough levels.

16 evels could be drawn, or incorrect timing of trough levels.

17 with lower Tac, but not CsA, dose-normalized trough levels.

18 A and everolimus in the same target range of trough levels.

19 is clinically useful even in the absence of trough levels.

20 ll P<0.001) but did not correlate with mTORi trough levels.

21 LCPT requires lower doses to achieve target trough levels.

22 on between LCP-Tacro tacrolimus exposure and trough levels.

23 ctory non-immunogenic patients with adequate trough-levels.

24 IS was defined as a median of Tac, CsA blood trough levels 12 hours after drug administration, or blo

25 was considered as a median of Tac, CsA blood trough levels 12 hours after drug administration, or blo

26 ng/mL); or convert to "reduced" TAC (target trough level 3.0-5.9 ng/mL) or "standard" TAC (target tr

27 either everolimus or sirolimus, n=33, target trough levels 3-8 ng/ml).

28 ther everolimus or sirolimus, n = 33, target trough levels 3-8 ng/mL).

29 and 2927 mg/y [IQR, 2377 to 3667 mg/y]) and trough levels (4.2 microg/mL [IQR, 2.6 to 5.8 microg/mL]

30 a 45-day course of intravenous cyclosporine (trough level 400-800 ng/ml).

31 tly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than

32 received steroids, reduced-dose CsA (target trough level 50% of full-dose range), and 1, 3, or 5 mg/

33 vel 3.0-5.9 ng/mL) or "standard" TAC (target trough level 6.0-8.9 ng/mL).

34 Vancomycin dosing did not influence initial trough levels; 78% were <10 ug/mL.

35 and 24 h after reperfusion), and tacrolimus (trough levels 8-12 ng/mL) was used for maintenance immun

36 t HIV-1 protease inhibitors maintain in vivo trough levels above their human serum protein binding-co

37 The median steady-state trough level achieved after dose escalation was 331 ng/m

38 who received enoxaparin adjusted by anti-Xa trough level (adjustment group) were compared with those

39 Tacrolimus trough levels along the first year were not different be

40 Tacrolimus trough levels along the first year were not different be

41 prednisone or tacrolimus dose or tacrolimus trough level and either the PD-L1/CD86 ratio on plasmacy

42 immunosuppressive drug (tacrolimus) dose or trough level and HLA-G expression or Treg frequency or F

43 Long-term target TAC trough level and MMF dosing were 5 to 7 ng/mL and 1,000

44 Adalimumab trough level and PASI score at the time of serum samplin

45 on sirolimus adjusted to a target rapamycin trough level and reduced-dose cyclosporine adjusted to t

46 s were not correlated with immunosuppressive trough levels and a selective increase was not observed

47 hocardiography, and blood sampling at plasma trough levels and after dosing.

48 ab - Observation Procedure: Adalimumab serum trough levels and anti-Adalimumab antibody (AAA) levels

49 Correlations between 12 h trough levels and AUC were r = 0.917 for generic tacroli

50 ombination therapies including MMF, at serum trough levels and higher, are toxic for the human bronch

51 Tacrolimus trough levels and laboratory values were closely monitor

52 year postoperatively, with lower tacrolimus trough levels and no difference in other adverse events.

53 gher BMI is associated with lower adalimumab trough levels and reduced treatment efficacy in NIU pati

54 nDSA) development correlates with tacrolimus trough levels and the recipient's individualized alloimm

55 aluate the impact of BMI on adalimumab serum trough levels and therapeutic efficacy in patients with

56 crolimus (0.15 mg/kg/day; 10-15 ng/mL target trough levels) and a tapered dose regimen of steroids.

57 ative immune induction, average cyclosporine trough level, and HLA mismatch.

58 The mean Tac dose, 12-hr trough level, and percentage of patients receiving maint

59 -ME dose reduction to maintain preconversion trough levels, and 64% of the patients attained their Cs

60 that HLA-DR/DQ eplet mismatch and tacrolimus trough levels are independent predictors of dnDSA develo

61 ulative data show that dose requirements and trough levels are similar between brand and generic tacr

62 icates that certain PK parameters, including trough levels, are correlated with clinical outcomes for

63 t patients who had routine monitoring of MMF trough level at the time of scheduled endomyocardial bio

64 then concentration-controlled to keep 24-hr trough levels at 10 to 12 ng/mL for 6 months and 5 to 10

65 , incidence of delay graft function, and Tac trough levels at different time points after transplanta

66 The mean (+/- SD) CsA trough levels at end point were 187 +/- 63 and 210 +/- 9

67 higher MMF exposure and elevated tacrolimus trough levels at M3.

68 ONCLUSION In patients with advanced GIST, IM trough levels at SS were associated with clinical benefi

69 nd clinical outcomes were correlated with IM trough levels at SS.

70 Mean trough levels at week 24 in the IV infusion series of 30

71 TAC trough levels at week two posttransplant were significan

72 sttransplant year, with (1) at least 3 blood trough levels available to calculate coefficient of vari

73 hin each race stratum, the mean cyclosporine trough levels averaged over 2-week intervals were nearly

74 initiated, the TAC dosage was skipped until trough levels began to decline; it was then administered

75 We analyzed the frequency of tacrolimus trough levels below a series of thresholds <6 ng/ml and

76 Levels of CsA were adjusted to maintain trough levels between 400 and 800 ng/ml.

77 nversion tacrolimus dose at each visit; mean trough levels between groups were similar.

78 Three measurements of CsA trough level, blood pressure, serum creatinine concentra

79 characterized by high peak and undetectable trough levels, both of which are required for male-speci

80 ine whether targeting a prophylactic anti-Xa trough level by adjusting the enoxaparin dose would redu

81 m level of uric acid, and blood cyclosporine trough level (C0) and used higher doses of cyclosporine

82 m level of uric acid, and blood cyclosporine trough level (C0) and used higher doses of cyclosporine

83 late and vitamin B12, and blood cyclosporine trough level (C0) are independently associated with tHcy

84 which is reflected in a rise of the predose trough level (C0).

85 3), and BUN (P=0.05), and blood cyclosporine trough level (C0, P=0.005) were independently associated

86 ents not infected with HIV, tacrolimus (TAC) trough levels (C0) or cyclosporine (CsA) drawn at C0 or

87 Mean TAC trough level (Cmin), used to adjust daily dose, was not

88 ors of systemically accessible targets where trough-level concentrations can sustain full target occu

89 Metformin plasma trough levels confirmed stable therapeutic exposure.

90 bulation), hospital discharge before initial trough levels could be drawn, or incorrect timing of tro

91 Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacro

92 (2) Trough levels did not differ between monotherapy and sta

93 and analyzed for association with tacrolimus trough levels during 1-y follow-up.

94 Careful monitoring of tacrolimus trough levels during concomitant chloramphenicol therapy

95 dme-miR-263a and -263b reach trough levels during the daytime, peak during the night

96 tentially meaningful changes in cyclosporine trough levels early in the postconversion course were us

97 urin inhibitor dose according to whole blood trough level, even though it overestimates the effective

98 ), an increased exposure might occur without trough levels exceeding the target range, resulting in "

99 he incidence of rejection in relation to MMF trough level following heart transplantation.

100 seline date: (1) supratherapeutic vancomycin trough level greater than 30 mug/mL, (2) trimethoprim-su

101 ssociated with treatment efficacy, including trough levels greater than 5 ug/ml.

102 rejection was noted in the samples with MMF trough level > or = mg/l compared to those with less tha

103 Ninety-six percent had at least 1 trough level >/=100 U/L.

104 Evl trough levels > or =3 ng/mL plus Tac are associated with

105 vo with concentration-controlled Evl (target trough levels > or =3 ng/mL) plus low-dose Tac or Evl pl

106 ants who maintained everolimus time-averaged trough levels >5 ng/mL during the first 2 months of ther

107 EVR trough levels >8 ng/mL were significantly associated wit

108 1.31]) compared to "conventional tacrolimus" trough levels (>10 ng/mL).

109 ant recipients with 50,011 serial tacrolimus trough levels had HLA-DR/DQ eplet mismatch determined us

110 Similar to younger recipients TAC trough level has also a high correlation (R = 0.76) with

111 ed by daily weights, chest radiographs, drug trough levels (high-performance liquid chromatography/ma

112 ightly, adjusted according to serum anti-HBs trough level) if they were HBsAg- and HBV-DNA negative a

113 clinically significant decrease in CsA 12-hr trough levels immediately after the institution of trogl

114 staggered group were the same or lower than trough levels in animals treated with either drug alone

115 atients with serum creatinine >3.0 mg/dl had trough levels in excess of the population mean (T: range

116 Mortality fell to trough levels in June 2020 (ICU: 22.5% [95% CI, 18.2-27.

117 le therapy was implemented for 120 days, and trough levels in serum were within or above the suggeste

118 Mean tacrolimus trough levels in the 6 months before dnDSA development w

119 Target SDZ RAD trough levels in the CTL group (no mAb) were 20-40 ng/ml

120 ariable analysis, high calcineurin inhibitor trough levels in the month before diagnosis (odds ratio

121 RAD and CsA day-14 trough levels in the staggered group were the same or lo

122 Trough levels increased from 45 to 132 ng/ml (P<0.001).

123 ther increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the

124 The C1-INH trough levels increased with C1-INH treatment.

125 Tacrolimus trough levels increased, and the dose was adjusted to ma

126 sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described.

127 he determination of optimal tacrolimus (TAC) trough levels is needed to prevent adverse effects of ca

128 In the case of trough level less than 5 ug/ml, patients treated with a

129 eiving C1H/Tac, patients with an average Tac trough level less than 6.5 ng/mL during the first 2 mont

130 s to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more

131 s > or = 2 mg/l compared to samples with MMF trough level <2 mg/l (3.6% vs. 14.4%, P=0.005).

132 dnDSA had a higher proportion of tacrolimus trough levels <5 ng/ml, which continued to be significan

133 We compared maximum 12-hr tacrolimus trough levels (MaxC0) and dose-adjusted MaxC0 in 12 case

134 Monitoring of MMF trough levels may play a role in the management of cardi

135 y weight assessment, chest radiographs, drug trough levels measured by high-performance liquid chroma

136 the steady-state drug exposure with a single trough-level measurement.

137 ic kidney recipients to a control group with trough-level monitoring of immunosuppressants or to an i

138 te rejection before month 3 (M3), tacrolimus trough levels more than 10 ng/mL, and M3 AUC0-12 hr more

139 y; day 8-28: 100 mg/kg/day; n=6; mean +/- SE trough level (MTL): 292+/-17 ng/ml) or SDZ RAD monothera

140 Patients with a trough level of 0.1 IU/mL or lower received enoxaparin s

141 ofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 microg/ml) or CsA (target trough

142 adjusted over time to maintain a whole-blood trough level of 12-15 ng/ml at 0-1 month, 10-12 ng/ml at

143 dosed twice daily to maintain a 12-hour drug-trough level of 150 ng/mL.

144 ated AAA (1243 ng/mL) with a mean adalimumab trough level of 3.0 ug/mL, significantly lower than the

145 ned randomly (1:1:1) to continue CsA (target trough level of 50-250 ng/mL); or convert to "reduced" T

146 nd given a sirolimus dose to achieve a 24-hr trough level of 8 to 14 ng/mL.

147 h level of 1.5-2.5 microg/ml) or CsA (target trough level of 80-100 ng/ml) in 60 pediatric patients w

148 At day 7 the blood trough level of FK506 in the FK506 group was 10-fold hig

149 antly lower rates of BPAR as compared with a trough level of less than 3 ng/mL.

150 Evl trough level of more than or equal to 3 ng/mL was associ

151 The targeted trough level of tacrolimus was between 8 and 10 ng/mL fo

152 as the coefficient of variation (CoV) of the trough level of the calcineurin inhibitor as a surrogate

153 icant graft survival occurred at whole blood trough levels of 0.5 ng/ml achieved at the 0.3 mg/kg/day

154 +/- 364 pg/mL (endogenous TPO) to predosing trough levels of 1, 840 +/- 353 pg/mL PEG-rHuMGDF (P = .

155 Sirolimus was increased to maintain trough levels of 12-15 ng/mL.

156 imen adjusted daily to maintain target 24 hr trough levels of 150-300 ng/ml CsA for poday 0 to poday

157 , Switzerland) and sirolimus with target CsA trough levels of 225 and 175 ng/mL at 1 month and 1 year

158 A therapeutic range of adalimumab trough levels of 3.51 mg/L to 7.00 mg/L, which correspon

159 0 +/- 300 pg/mL 2 hours after injection with trough levels of 300 +/- 65 pg/mL before the next dose.

160 Maintenance target 12-hr tacrolimus trough levels of 5 to 7 ng/mL were operational from the

161 500 mg twice daily) and tacrolimus (targeted trough levels of 5 to 7 ng/ml) and no corticosteroid the

162 g at 3mg/m(2) /day (titrated to target blood trough levels of 5-15ng/ml).

163 ith dose adjustments to maintain whole blood trough levels of 8-15 ng/mL by IMx.

164 ensitivity to PEGasparaginase had serum mean trough levels of 899 U/L.

165 uppression was reduced to achieve tacrolimus trough levels of approximately 8 ng/mL and prednisone at

166 nt between mice UV-irradiated during peak or trough levels of cyclosporine in the blood.

167 pigs had greater T cell depletion and higher trough levels of cyclosporine.

168 losporin A, resulting in significantly lower trough levels of everolimus (3.5 versus 4.5 ug/L, P<0.00

169 Trough levels of FK506 were not predictive for the devel

170 to-count recovery was associated with higher trough levels of gilteritinib, which, in turn, were asso

171 cation Assessment Questionnaire scale, serum trough levels of immunosuppressants, and pharmacy refill

172 Patients were closely monitored for trough levels of immunosuppressive agents, laboratory va

173 (BP), hemoglobin, serum creatinine, lipids, trough levels of immunosuppressive drugs, and daily prot

174 tion, echocardiography, and blood samples at trough levels of intervention, and then during a 4-hour

175 Patients with very low trough levels of less than 4 g/L had poor clinical outco

176 s have significantly (P=0.001) higher 1-year trough levels of mycophenolic acid (4.16 ng/mL) than cyc

177 Pronounced elevations in trough levels of nitric oxide metabolites occurred with

178 Overall, 97% of all trough levels of nonallergic patients were > 100 IU/L.

179 stem recovered bacteria only in bottles with trough levels of piperacillin-tazobactam.

180 KNO3 increased trough levels of serum nitric oxide metabolites after 6

181 oup (23% versus 15%, P = 0.04) due to higher trough levels of Tacrolimus on month 3 (9.48 versus 7.30

182 The 12-hour trough levels of tacrolimus were significantly higher in

183 Trough levels of tacrolimus were significantly lower in

184 e similar doses of corticosteroids and lower trough levels of tacrolimus, compared with 15% of white

185 mes compared with BSX and could permit lower trough levels of Tacrolimus, thus reducing occurrence of

186 No correlation between ribavirin trough level on day 7 or at month 2 with a virological r

187 eater incidence of subtherapeutic tacrolimus trough levels on postoperative day 7.

188 tes differed among the quartiles of imatinib trough levels (P = .01 for CCyR, P = .02 for MMR).

189 hich correlated with undetectable adalimumab trough levels (P = 0.014).

190 s observed between AAA titers and adalimumab trough levels (P = 0.2).Concomitant immunosuppression di

191 Trough level plasma samples were obtained on day 29 (ste

192 Target tacrolimus trough levels postoperatively were 10, 8, and 6 ng/mL at

193 day 105 correlated inversely with sirolimus trough levels (R2=0.67, P<0.05).

194 re maintained on tacrolimus monotherapy with trough levels ranging between 4 and 12 ng/mL.

195 Because SD increased as mean trough levels rose, CV% (CV%=SD/mean multiplied by 100%)

196 Time-averaged everolimus trough levels significantly correlated with greater inhi

197 Initial and 3- to 6-month cyclosporin A trough level targets were 250 to 300 and 225 to 275 ng/m

198 5 expressers tended to have lower tacrolimus trough levels than nonexpressers, although their tacroli

199 nts on ritonavir-containing cART and raising trough levels to achieve an exposure equivalent to HIV-n

200 Groups were stratified by both Evl and Tac trough levels to evaluate glomerular filtration rate and

201 to correlate the risk of proteinuria to EVR trough levels up to 24 months posttransplant.

202 Sirolimus remained > 5 mug/L, the trough level used in oral immunosuppressive therapy, for

203 B1 on tacrolimus dose requirements and blood trough level variability in the period immediately after

204 f rejection decreased significantly when MMF trough level was > or = 2 mg/l compared to samples with

205 However, in group B, the target tacrolimus trough level was 4 to 7 ng/mL to reduce long-term nephro

206 Imatinib plasma trough level was performed at day 22 and if <1000 ng/mL,

207 roviding 3 adjusted doses of enoxaparin, the trough level was redrawn and the dosage was adjusted as

208 oups, despite the fact that the mean SDZ RAD trough level was significantly lower in the CD25 group (

209 Resting CO at trough levels was higher after KE compared with isocalor

210 Mean prednisone dose and cyclosporine trough level were higher in the women than the men (P<0.

211 Target tacrolimus trough levels were 10 and 8 ng/mL at 1 month and 1 year,

212 Target CsA trough levels were 100-200 ng/ml.

213 ) than preconversion tacrolimus dose; target trough levels were 4-15 ng/mL.

214 Maintenance sirolimus target trough levels were 8 ng/mL in groups A and C.

215 Tacrolimus trough levels were 9.3+/-2.4 ng/ml (off steroids) and 9.

216 L had poor clinical outcomes, whereas higher trough levels were associated with a reduced frequency o

217 Higher DIN trough levels were associated with response.

218 Deviations in trough levels were avoided, thus preventing any clinical

219 Tacrolimus trough levels were checked during nirmatrelvir/ritonavir

220 ance: In this study, subprophylactic anti-Xa trough levels were common in trauma patients.

221 Baseline characteristics and mean tacrolimus trough levels were comparable between arms.

222 henolate mofetil dose nor tacrolimus dose or trough levels were different between those with or witho

223 serum daclizumab and mycophenolic acid (MPA) trough levels were evaluated.

224 Overall, adalimumab trough levels were higher in responder patients.

225 The target 12-hr Tac trough levels were lowered to 4 to 6 ng/mL in the signif

226 Tacrolimus (TAC) and mycophenolic acid (MPA) trough levels were measured from 1 to 12 months posttran

227 Exposures: Anti-Xa trough levels were monitored in patients in the adjustme

228 Trough levels were monitored.

229 Steady-state trough levels were obtained after 6 weeks of therapy; pa

230 loratory analysis demonstrated that imatinib trough levels were predictive of higher CCyR independent

231 Tacrolimus trough levels were readily achieved posttransplant; init

232 SIR doses and trough levels were significantly higher in the SIR-LD pa

233 ter the first year posttransplant, CsA 12-hr trough levels were significantly lower in late rejection

234 ted in HIV-negative recipients, when similar trough levels were targeted.

235 ed on LCP-Tacro once-daily for days 8 to 21; trough levels were to be maintained between 5 and 15 ng/

236 rences in tacrolimus exposure in the 2 arms; trough levels were toward the upper end of the low-expos

237 Neoral resulted in significantly higher LFM trough levels when compared to LFM monotherapy.

238 There were no differences in mean doses or trough levels when comparing the two study groups.

239 Therapeutic monitoring is based on mTORi trough levels, which do not necessarily reflect biologic

240 te the biological effects of normalizing AAT trough levels with double-dose (DD) therapy (120 mg/kg/w

241 uration of dose-corrected tacrolimus predose trough levels with time after transplantation.

242 patients with therapeutic immunosuppressive trough levels, with or without first inducing ACR.

243 old immediately before each meal and fell to trough levels within 1 h after eating, a pattern recipro

244 Lack of variation of 5-FU trough levels within a day at steady-state indicates sup

245 ing method could improve maintenance of drug trough levels within pre-determined target ranges, focus